

# Marta Reina-Couto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/399343/publications.pdf>

Version: 2024-02-01

12  
papers

249  
citations

1162367

8  
h-index

1372195

10  
g-index

12  
all docs

12  
docs citations

12  
times ranked

391  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. <i>Frontiers in Physiology</i> , 2021, 12, 746494.	1.3	56
2	Endocan: A novel biomarker for risk stratification, prognosis and therapeutic monitoring in human cardiovascular and renal diseases. <i>Clinica Chimica Acta</i> , 2020, 509, 310-335.	0.5	21
3	Gut bacterial microbiome composition and statin intake—A systematic review. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00601.	1.1	31
4	Role of Oxidative Stress in the Pathophysiology of Arterial Hypertension and Heart Failure. , 2019, , 509-537.		3
5	Aspirin and blood pressure: Effects when used alone or in combination with antihypertensive drugs. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2017, 36, 551-567.	0.2	3
6	Aspirin and blood pressure: Effects when used alone or in combination with antihypertensive drugs. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 551-567.	0.2	12
7	Regulation of the Renin-Angiotensin-Aldosterone System by Reactive Oxygen Species. , 2017, , .		5
8	Research update for articles published in <sc>EJCI</sc> in 2014. <i>European Journal of Clinical Investigation</i> , 2016, 46, 880-894.	1.7	2
9	Estatinas e stresse oxidativo na insuficiÃªncia cardÃ¡ca crÃ³nica. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 41-57.	0.2	36
10	Statins and oxidative stress in chronic heart failure. <i>Revista Portuguesa De Cardiologia (English)</i> Tj ETQq0 0 0 rgBT /Oyerlock 10 Tf 50 38	0.2	24
11	Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators. <i>Current Drug Targets</i> , 2016, 17, 1206-1223.	1.0	13
12	Impaired resolution of inflammation in human chronic heart failure. <i>European Journal of Clinical Investigation</i> , 2014, 44, 527-538.	1.7	43